Cargando…

382 Strategies for commercializing non-patentable innovations developed at CTSA hubs

OBJECTIVES/GOALS: This presentation reports activities of a NCATS-funded collaborative working group created to promote dissemination and implementation (D&I) research within the CTSA landscape. Our working group seeks to meet both the conceptual as well as practical challenges to advancing the...

Descripción completa

Detalles Bibliográficos
Autores principales: Quanbeck, Andrew, Saha-Muldowney, Mondira, Mahoney, Jane, Garza-Hennessy, Rose, Meline, Rachael, Hirschfield, Sheena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209143/
http://dx.doi.org/10.1017/cts.2022.217
_version_ 1784729878446211072
author Quanbeck, Andrew
Saha-Muldowney, Mondira
Mahoney, Jane
Garza-Hennessy, Rose
Meline, Rachael
Hirschfield, Sheena
author_facet Quanbeck, Andrew
Saha-Muldowney, Mondira
Mahoney, Jane
Garza-Hennessy, Rose
Meline, Rachael
Hirschfield, Sheena
author_sort Quanbeck, Andrew
collection PubMed
description OBJECTIVES/GOALS: This presentation reports activities of a NCATS-funded collaborative working group created to promote dissemination and implementation (D&I) research within the CTSA landscape. Our working group seeks to meet both the conceptual as well as practical challenges to advancing the utilization of D&I across the translational science spectrum. METHODS/STUDY POPULATION: A fundamental focus of D&I is supporting the movement of effective health interventions into real-world use so that they benefit population health. Yet, this process remains unpredictable, with some interventions receiving widespread uptake in practice and others (of similar potential benefit) failing to translate. The value of research efforts is wasted when directed toward the “wrong” interventions. Recent discussion and experience amongst investigators in our collaborative working group has resulted in new ways of addressing this problem. Specifically, tools borrowed from business and management have shown promise in predicting which health interventions have the highest potential for commercialization and dissemination. RESULTS/ANTICIPATED RESULTS: We will conduct an environmental scan of CTSA hubs to understand their approaches to supporting commercialization and business development around research products, identifying the most promising and effective methods and processes. We will compile various tools for identifying and supporting interventions with the highest potential for commercialization, including how to form the multidisciplinary and stakeholder-engaged teams necessary to make these determinations. Finally, we will further explore the differences between patentable and non-patentable innovations and make recommendations for CTSAs in supporting the latter. DISCUSSION/SIGNIFICANCE: Commercialization of non-patentable interventions is an essential and underexplored element of the translational science spectrum. The perspectives and methods of D&I should not be relegated to late-stage translational steps, but rather inform the conduct of translational science writ large.
format Online
Article
Text
id pubmed-9209143
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-92091432022-07-01 382 Strategies for commercializing non-patentable innovations developed at CTSA hubs Quanbeck, Andrew Saha-Muldowney, Mondira Mahoney, Jane Garza-Hennessy, Rose Meline, Rachael Hirschfield, Sheena J Clin Transl Sci Valued Approaches OBJECTIVES/GOALS: This presentation reports activities of a NCATS-funded collaborative working group created to promote dissemination and implementation (D&I) research within the CTSA landscape. Our working group seeks to meet both the conceptual as well as practical challenges to advancing the utilization of D&I across the translational science spectrum. METHODS/STUDY POPULATION: A fundamental focus of D&I is supporting the movement of effective health interventions into real-world use so that they benefit population health. Yet, this process remains unpredictable, with some interventions receiving widespread uptake in practice and others (of similar potential benefit) failing to translate. The value of research efforts is wasted when directed toward the “wrong” interventions. Recent discussion and experience amongst investigators in our collaborative working group has resulted in new ways of addressing this problem. Specifically, tools borrowed from business and management have shown promise in predicting which health interventions have the highest potential for commercialization and dissemination. RESULTS/ANTICIPATED RESULTS: We will conduct an environmental scan of CTSA hubs to understand their approaches to supporting commercialization and business development around research products, identifying the most promising and effective methods and processes. We will compile various tools for identifying and supporting interventions with the highest potential for commercialization, including how to form the multidisciplinary and stakeholder-engaged teams necessary to make these determinations. Finally, we will further explore the differences between patentable and non-patentable innovations and make recommendations for CTSAs in supporting the latter. DISCUSSION/SIGNIFICANCE: Commercialization of non-patentable interventions is an essential and underexplored element of the translational science spectrum. The perspectives and methods of D&I should not be relegated to late-stage translational steps, but rather inform the conduct of translational science writ large. Cambridge University Press 2022-04-19 /pmc/articles/PMC9209143/ http://dx.doi.org/10.1017/cts.2022.217 Text en © The Association for Clinical and Translational Science 2022 https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
spellingShingle Valued Approaches
Quanbeck, Andrew
Saha-Muldowney, Mondira
Mahoney, Jane
Garza-Hennessy, Rose
Meline, Rachael
Hirschfield, Sheena
382 Strategies for commercializing non-patentable innovations developed at CTSA hubs
title 382 Strategies for commercializing non-patentable innovations developed at CTSA hubs
title_full 382 Strategies for commercializing non-patentable innovations developed at CTSA hubs
title_fullStr 382 Strategies for commercializing non-patentable innovations developed at CTSA hubs
title_full_unstemmed 382 Strategies for commercializing non-patentable innovations developed at CTSA hubs
title_short 382 Strategies for commercializing non-patentable innovations developed at CTSA hubs
title_sort 382 strategies for commercializing non-patentable innovations developed at ctsa hubs
topic Valued Approaches
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209143/
http://dx.doi.org/10.1017/cts.2022.217
work_keys_str_mv AT quanbeckandrew 382strategiesforcommercializingnonpatentableinnovationsdevelopedatctsahubs
AT sahamuldowneymondira 382strategiesforcommercializingnonpatentableinnovationsdevelopedatctsahubs
AT mahoneyjane 382strategiesforcommercializingnonpatentableinnovationsdevelopedatctsahubs
AT garzahennessyrose 382strategiesforcommercializingnonpatentableinnovationsdevelopedatctsahubs
AT melinerachael 382strategiesforcommercializingnonpatentableinnovationsdevelopedatctsahubs
AT hirschfieldsheena 382strategiesforcommercializingnonpatentableinnovationsdevelopedatctsahubs